Status:
UNKNOWN
Prognostic Value of Plasma Biomarkers Among Patients With Hypertension
Lead Sponsor:
Beijing Institute of Heart, Lung and Blood Vessel Diseases
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
Hypertension is the most important risk factor for cardiovascular and cerebrovascular diseases，and also a substantial public health problem. The purpose of the study is to investigate the association ...
Eligibility Criteria
Inclusion
- \>18 years old
- In accordance with the diagnosis of hypertension (BP≥140/90mmHg)
Exclusion
- The exclusion Criteria for the study program were as follows:
- Pregnancy, history of heart failure or left ventricular ejection fraction less than 40%, myocardial infarction within one month, percutaneous transluminal coronary angioplasty or coronary artery bypass grafting, cerebrovascular disease, severe liver disease, severe chronic renal failure (eGFR less than 30 mL/min/1.73 m2) in the past three months.
Key Trial Info
Start Date :
April 1 2017
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
August 1 2022
Estimated Enrollment :
600 Patients enrolled
Trial Details
Trial ID
NCT04107584
Start Date
April 1 2017
End Date
August 1 2022
Last Update
September 27 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Beijing Anzhen Hospital
Beijing, Beijing Municipality, China, 100029